"The beauty of optical imaging is the breadth of instrumentation and reporters that have been developed to enable visualization of structures from the cm to sub-micron range in vivo."
I joined Genentech in 2006, and have been impressed with its collaborative environment, world-class science and continued focus on clinical questions. My lab collaborates across the research and early clinical development organizations. Our goal is to develop and implement imaging-based technologies to enable in vivo studies of disease biology and potential therapeutic approaches.
The postdoctoral program at Genentech provides a unique and exciting training opportunity. I am interested in understanding the mechanisms that regulate the stability of neuronal synaptic connections in vivo. Postdoctoral projects within my lab are focused on understand cell intrinsic and extrinsic pathways that influence the stability of these connections both in naive and disease paradigms. We rely on morphological and functional 2-photon in vivo imaging paradigms in combination with molecular genetic manipulations to study the interplay between neurons and glia in regulating synaptic connectivity.
My lab is focused on combining optical imaging technologies with cellular and molecular tools to study the pathophysiology of human disease in vivo. The beauty of optical imaging is the breadth of instrumentation and reporters that have been developed to enable visualization of structures from the cm to sub-micron range in vivo. We utilize bioluminescence imaging, planar near-infrared fluorescence imaging, optical coherence tomography and 2-photon microscopy to span this range of resolution. Our instrumentation base is supported by a growing list of probes and transgenic models that report aspects of animal physiology, disease pathology, and cellular physiology. Combined, we can examine cellular and sub-cellular behavior in conjunction with physiological readouts to better understand disease progression in vivo and assess mechanisms of action of potential therapeutics.